Leadership Overview
Novotech has 8 executives leading key functions including strategy, finance, operations, medical affairs, marketing, human resources, and business development.
Dedicated to advancing novel therapeutics, Novotech drives innovation by partnering with biotech companies to accelerate drug development across all phases of clinical research.
Dedicated to advancing novel therapeutics, Novotech drives innovation by partnering with biotech companies to accelerate drug development across all phases of clinical research.
Leadership Roles at Novotech
Federico Freyria - Chief Executive Officer
Federico Freyria, the Chief Executive Officer at Novotech, directs the company's overarching strategy and global operations. Overseeing all business units, Federico Freyria ensures alignment with Novotech's mission to accelerate the development of advanced therapeutics for biotech partners. This leadership role involves driving market expansion and fostering strategic partnerships across the global pharmaceutical landscape. By championing innovation, Federico Freyria guides the organization in navigating complex regulatory environments and clinical trial processes. The Chief Executive Officer's focus remains on enhancing Novotech's position as a premier full-service clinical Contract Research Organization (CRO), delivering exceptional value and advancing patient care through novel treatments. This executive's strategic vision underpins the company's commitment to scientific excellence and operational efficiency, ensuring sustained growth and impact in the biopharmaceutical sector.
Ekaterina Galperina - Chief Financial Officer
Ekaterina Galperina, the Chief Financial Officer at Novotech, manages all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and financial reporting, Ekaterina Galperina ensures the fiscal health and sustainability of the organization. This critical role involves managing investment strategies and optimizing financial resources to support Novotech's global expansion and research initiatives. By maintaining robust financial controls, the Chief Financial Officer safeguards company assets and drives profitability. Ekaterina Galperina's expertise is vital in securing funding and managing financial relationships with stakeholders, directly contributing to the company's ability to partner with biotech firms. The Chief Financial Officer's leadership ensures that financial decisions align with Novotech's mission to accelerate the development of novel therapeutics, reinforcing the company's market position.
Hussein AlRoz - Chief Operating Officer
Hussein AlRoz, the Chief Operating Officer at Novotech, directs the company's global operational execution and service delivery. Overseeing clinical trial management, project execution, and operational efficiency, Hussein AlRoz ensures seamless service delivery to biotech partners. This leadership position involves optimizing resource allocation and implementing best practices across all operational departments. By driving operational excellence, the Chief Operating Officer enhances Novotech's capacity to manage complex clinical research projects. Hussein AlRoz's focus is on streamlining processes and improving workflow to accelerate therapeutic development timelines. The Chief Operating Officer's strategic oversight is fundamental to Novotech's commitment to providing comprehensive, full-service CRO capabilities, reinforcing the company's reputation for reliability and speed in advancing novel treatments.
Funsho Ojebuoboh - President & Owner
Funsho Ojebuoboh, the President & Owner at Novotech, holds ultimate responsibility for the company's strategic direction and long-term vision. Overseeing all facets of the business, Funsho Ojebuoboh ensures Novotech remains at the forefront of clinical research services for biotech innovators. This leadership position involves guiding strategic investments and fostering a culture of excellence and innovation. By providing ownership-level oversight, the President & Owner drives the company's commitment to accelerating the development of advanced therapeutics. Funsho Ojebuoboh's influence shapes Novotech's operational framework and market approach, ensuring sustained growth and impact. The President & Owner's dedication to the company's mission reinforces Novotech's role as a vital partner in bringing novel treatments to patients worldwide.
Joseph Dumais - President
Joseph Dumais, the President at Novotech, drives strategic initiatives and operational excellence across key business segments. Overseeing critical functions, Joseph Dumais ensures seamless execution of Novotech's mission to accelerate therapeutic development for biotech partners. This leadership role involves fostering cross-functional collaboration and optimizing service delivery to meet client needs. By championing operational efficiency, the President enhances Novotech's capacity to manage complex clinical trials. Joseph Dumais's focus is on strengthening the company's global presence and expanding its service offerings. The President's strategic guidance is essential for Novotech's continued success in the biopharmaceutical landscape, supporting the advancement of novel treatments and improving patient access to innovative therapies.
Melinda Borrelli - Head of Medical Office Chief & Chief Marketing Officer, Operations
Melinda Borrelli, the Head of Medical Office Chief & Chief Marketing Officer, Operations at Novotech, leads both the strategic direction of medical affairs and the company's global marketing initiatives. Overseeing clinical strategy development and market positioning, Melinda Borrelli ensures Novotech's services effectively reach and resonate with biotech clients. This dual role involves driving medical excellence and crafting compelling marketing campaigns that highlight Novotech's expertise in accelerating therapeutic development. By integrating medical insights with marketing strategies, Melinda Borrelli enhances the company's brand visibility and client engagement. The Head of Medical Office Chief & Chief Marketing Officer, Operations' leadership is crucial for communicating Novotech's value proposition and fostering strong relationships within the biopharmaceutical ecosystem, supporting the company's mission to advance novel treatments.
Tim Bray - Chief Human Resources Officer
Tim Bray, the Chief Human Resources Officer at Novotech, leads the company's talent management and organizational development strategies. Overseeing recruitment, employee relations, and HR policy implementation, Tim Bray ensures Novotech cultivates a high-performing and engaged workforce. This executive role is pivotal in attracting and retaining top talent essential for driving innovation in clinical research. By fostering a positive and supportive work environment, the Chief Human Resources Officer contributes directly to Novotech's ability to deliver exceptional services to its biotech partners. Tim Bray's leadership focuses on developing human capital to meet the evolving demands of the biopharmaceutical industry. The Chief Human Resources Officer's strategic approach to workforce planning supports Novotech's mission to accelerate the development of novel therapeutics through expert personnel.
Judith Ng-Cashin - Chief Medical Officer
Judith Ng-Cashin, the Chief Medical Officer at Novotech, provides critical medical and scientific leadership across all clinical development programs. Overseeing the medical strategy and ensuring scientific rigor, Judith Ng-Cashin guides Novotech's partnerships with biotech companies in advancing novel therapeutics. This role involves providing expert clinical insights, ensuring compliance with regulatory standards, and driving the scientific direction of research projects. By leveraging extensive medical expertise, the Chief Medical Officer enhances the quality and efficiency of clinical trials. Judith Ng-Cashin's leadership is instrumental in translating scientific innovation into tangible therapeutic advancements. The Chief Medical Officer's commitment to medical excellence supports Novotech's core mission of accelerating drug development and improving patient outcomes globally.
Explore Leadership Teams in Business Services
PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management, and biostatistical analysis, epidemiology and health economics/outcomes research, clinical supply and drug logistics, pharmacovigilance, commercialization, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization, and strategic compliance; and market and product development, and targeted communications services to support product launch, as well as offers solutions to address client issues associated with product development, registration, and commercialization. The PI segment provides information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, IMPACT clinical trial management systems, LIQUENT InSight regulatory information management software and professional services, DataLabs electronic data capture systems, Web-based portals, systems integration services, electronic patient reported outcomes, and patient diary applications, as well as centralized assessment services for patient technology solutions. PAREXEL International Corporation was founded in 1983 and is headquartered in Waltham,...
Company Leadership DT
PA
Canadian Nuclear Laboratories (CNL) is Canadas premier nuclear science and technology organization. CNL has been a world leader in developing peaceful and innovative applications from nuclear technology through its expertise in physics, metallurgy, chemi
Company Leadership ML
HC
Embrapa (Brazilian Agricultural Research Corporation) is a Brazilian public research institution headquartered in Brasilia, Brazil. Founded in 1973 and linked to the Ministry of Agriculture, Embrapa conducts agricultural research and development to improve productivity, sustainability, and competitiveness of Brazilian agriculture. The organization operates a network of research centers across Brazil.
Company Leadership SM
RC
FO
Founded in 1985, Pharmaceutical Product Development (PPD) is a contract research organization engaging in drug discovery, development and lifecycle management for clients from pharmaceutical, biotechnological, medical device, academic and government organizations.
Company Leadership LE
FS
MW
Frequently Asked Questions Regarding Novotech Top Executives and Leadership Team
